Buy Lucentis solution 10 mg/ml 0.23
  • Buy Lucentis solution 10 mg/ml 0.23

Lucentis [Ranibizumab]

Novartis
1344 Items
2019-09-19
Dosage form
Brand & Manufacturer
Package Size
$2,088.31
Quantity
  • done All payments are SSL encrypted
  • done Full Refund if you haven't received your order
  • done International shipping to the USA, UK and Europe

Clinical Pharmacology

Lucentis has an inhibitory angiogenesis effect. With the introduction of ranibizumab into the vitreous (1 time per month) to patients with neovascular age-related macular degeneration (AMD) Cmax in blood plasma was low and insufficient for inhibiting the biological activity of VEGF-A by 50% (11–27 ng / ml according to cell proliferationin vitro). With the introduction of the drug into the vitreous body in the dose range from 0.05 to 1.0 mg. Cmax ranibizumab in plasma was proportional to its dosage. Based on the results of pharmacokinetic analysis and taking into account the removal of ranibizumab from blood plasma, the average T1/2 drug (dose of 0.5 mg) of the vitreous body averaged about 9 days.

With the introduction of the drug Lucentis into the vitreous body (1 time per month) CmaxPlasma ranibizumab is reached within one day after the injection and is in the range of 0.79–2.90 ng / ml. Cmin ranibizumab in plasma is in the range of 0.07–0.49 ng / ml. The concentration of ranibizumab in the serum is approximately 90000 times lower than that in the vitreous body.

Indications

Treatment of the neovascular (wet) form of age-related macular degeneration in adults.

Treatment of reduced visual acuity associated with diabetic edema of the macula as monotherapy or in combination with laser coagulation (LC) in patients who have previously had LC.

Composition

1 ml. contains ranibizumab 10 mg.

No customer reviews for the moment.

Write your review

Write your review

Lucentis [Ranibizumab]

Dosage and Administration

The recommended dose of Lucentis is 0.5 mg (0.05 ml) 1 time per month as an injection into the vitreous body. The first 3 injections of the drug Lucentis are performed with a frequency of 1 time per month consistently for 3 months, then treatment with the drug is stopped (stabilization phase) and visual acuity is checked regularly (at least 1 time per month) .. When visual acuity decreases by more than 5 letters on the ETDRS scale (1 line in the Snellen table), drug treatment is resumed.

Before the introduction of the drug Lucentis should monitor the quality of dissolution and color of the solution. The drug can not be used when changing the color of the solution and the appearance of insoluble visible particles.

Injection of the drug into the vitreous body should be carried out in aseptic conditions, including the processing of the hands of health workers, the use of sterile gloves, napkins, a bile expander (or its equivalent) and, if necessary, tools for paracentesis.

Before the introduction of the drug, it is necessary to conduct appropriate disinfection of the skin of the eyelids and the area around the eyes, anesthesia of the conjunctiva and therapy with a broad spectrum antimicrobial preparations.

Antimicrobial drugs should be instilled into the conjunctival sac 3 times a day for 3 days before and after the injection.

The drug Lucentis should be injected into the vitreous 3.5–4 mm posterior to the limbus, avoiding the horizontal meridian and directing the needle to the center of the eyeball. The volume of the injected drug is 0.05 ml.

The next injection of the drug is carried out in the other half of the sclera. Since intraocular pressure may increase within 60 minutes after the injection of Lucentis, it should be monitored, the optic nerve disc perfused and, if necessary, appropriate treatment should be applied.

During one session, the administration of the drug Lucentis is carried out only in one eye.

Adverse reactions

The study of the safety of the drug was carried out during clinical studies in 1315 patients for 2 years. Serious adverse events associated with the drug administration procedure included endophthalmitis, rhegmatogenous retinal detachment, and cataracts due to iatrogenic trauma. Other serious adverse effects observed with the drug Lucentis, included intraocular inflammation and increased intraocular pressure.

The following adverse events (possibly associated with the use of the drug) were observed in a frequency of not less than 2% in patients receiving the drug Lucentis 0.5 mg compared with the control group (imitation injection or photodynamic therapy).

The incidence of adverse events was assessed as follows: occurring very often (≥1 / 10), often (≥1 / 100;

Infections and invasions: very often nasopharyngitis; often - the flu.

From the hemopoietic system: often anemia.

Mental disorders: often anxiety.

From the nervous system: very often - headache; sometimes a stroke.

On the part of the organ of vision: very often, intraocular inflammation, vitreous inflammation, vitreous detachment, retinal hemorrhages, visual disturbances, eye pain, vitreous opacities, increased intraocular pressure, conjunctival hemorrhages, eye irritation, feeling of "foreign body" in the eyes, tears , dry eye syndrome, redness of the eyes, itching sensation in the eyes; often - degenerative changes of the retina, retinal damage, retinal detachment, retinal tears, detachment of retinal pigment epithelium, pigment epithelium tear, reduced visual acuity, bleeding into the vitreous, vitreous loss, uveitis, iritis, iridocyclitis, cataracts, subcapsular cataract, blurred rear lens capsules, punctate keratitis, corneal erosion, cellular opalescence in the anterior chamber, blurred vision,hemorrhage at the injection site, eye hemorrhage, conjunctivitis, allergic conjunctivitis, eye discharge, photopsia, photophobia, discomfort in the eyes, eyelid edema, eyelid soreness, conjunctival hyperemia; sometimes - blindness, endophthalmitis, hypopyon, hyphema, keratopathy, iris adhesions, deposits in the cornea, corneal edema, striae of the cornea, pain and irritation at the injection site, atypical sensations in the eye and eyelid irritation.

On the part of the respiratory system: often cough.

From the digestive system: often nausea.

Dermatological disorders: often - allergic reactions (rash, urticaria, itching).

From the musculoskeletal system: very often - arthralgia.

Contraindications

Carefully: in patients with a history of known hypersensitivity, in the presence of risk factors for the development of stroke, the drug should be administered only after a thorough assessment of the risk / benefit ratio.

Drug interactions

The interaction of the drug Lucentis with other drugs has not been studied. The drug Lucentis should not be mixed with any other drugs or solvents.

Special instructions

To conduct drug treatment should only an ophthalmologist who has experience in performing intravitreal injections.

The introduction of the drug Lucentis should always be carried out in aseptic conditions. In addition, within 1 week after the injection of the drug, it is necessary to monitor the patient in order to identify a possible local infection process and timely therapy. Patients should be informed of the need to immediately report to the doctor about all the symptoms that may indicate the development of endophthalmitis.

With the injection into the vitreous body of inhibitors of endothelial growth factor A (VEGF-A), arterial thromboembolic complications may develop.

With the injection into the vitreous body of inhibitors of endothelial growth factor A (VEGF-A), arterial thromboembolic complications may develop.

The risk of developing a stroke may be higher if the patient has risk factors, including a previous stroke or transient cerebral circulation in history.

When conducting drug therapy in women of childbearing age, you should use reliable methods of contraception.

Overdosage

Symptoms: in clinical studies and with the use of the drug in clinical practice there have been cases of unintentional overdose of the drug. In these cases, with an overdose of Lucentis, an increase in intraocular pressure and pain in the eye were most often observed.

Treatment: in case of drug overdose, intraocular pressure must be monitored; if necessary, the patient should be under the supervision of a physician.

  • Brand name: Lucentis
  • Active ingredient: Ranibizumab

Studies and clinical trials of Ranibizumab (Click to expand)

  1. Bevacizumab and ranibizumab on microvascular endothelial cells: A comparative study
  2. ISRCTN12125882 - Influence of topical anti-VEGF (Ranibizumab) on the outcome of filtration surgery for glaucoma - Study Protocol
  3. Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration
  4. Ranibizumab bei Makuladegeneration. Angiogenese-Hemmung gegen Sehverlust
  5. Behandlung einer traumatischen chorioidalen Neovaskularisation mit Ranibizumab
  6. Frühzeitige Behandlung mit Ranibizumab (Lucentis®) bei exsudativer AMD
  7. Qualitätsunterschiede zwischen Ranibizumab aus Originalbehältern und aus Fertigspritzen
  8. Retinal pigment epithelial tear following intravitreal ranibizumab injections for neovascular age-related macular degeneration
  9. Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells
  10. Ranibizumab for retinal angiomatous proliferation in neovascular age-related macular degeneration
  11. Intravitreal ranibizumab (Lucentis) for choroidal neovascularization associated with Stargardt’s disease
  12. Combined photodynamic therapy and intravitreal ranibizumab as primary treatment for subretinal neovascular membrane (SRNVM) associated with type 2 idiopathic macular telangiectasia
  13. Persisent ocular hypertension following intravitreal ranibizumab
  14. Cost-effectiveness sequential modeling of ranibizumab versus usual care in age-related macular degeneration
  15. Are intravitreal bevacizumab and ranibizumab effective in a rat model of choroidal neovascularization?
  16. Intravitreal ranibizumab (Lucentis®) for the treatment of myopic choroidal neovascularization
  17. Intravitreal ranibizumab (Lucentis®) in the treatment of retinal angiomatous proliferation (RAP)
  18. Intravitreal ranibizumab for choroidal neovascularization related to traumatic Bruch’s membrane rupture
  19. Intravitreal ranibizumab as primary treatment for neovascular membrane associated with idiopathic juxtafoveal retinal telangiectasia
  20. Different properties of VEGF-antagonists: Bevacizumab but not Ranibizumab accumulates in RPE cells
  21. Intravitreal ranibizumab (Lucentis) for treatment of central retinal vein occlusion: a prospective study
  22. Early neovascular bridging of choroidal neovascularization after ranibizumab treatment
  23. Cost-effectiveness of ranibizumab compared with pegaptanib in neovascular age-related macular degeneration
  24. Ranibizumab for retinal angiomatous proliferation

8 other products in the same category:

arrow_upward